Jean Holloway Net Worth

The estimated Net Worth of Jean F Holloway is at least 3 百万$ dollars as of 31 August 2021. Ms. Holloway owns over 663 units of Artivion Inc stock worth over 1,547,818$ and over the last 10 years she sold CRY stock worth over 60,362$. In addition, she makes 1,391,060$ as Senior Vice President、 Chief Compliance Officer、 General Counsel、 Secretary at Artivion Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Holloway CRY stock SEC Form 4 insiders trading

Jean has made over 14 trades of the Artivion Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she sold 663 units of CRY stock worth 17,563$ on 31 August 2021.

The largest trade she's ever made was exercising 10,000 units of Artivion Inc stock on 1 May 2019 worth over 102,400$. On average, Jean trades about 1,494 units every 48 days since 2015. As of 31 August 2021 she still owns at least 86,567 units of Artivion Inc stock.

You can see the complete history of Ms. Holloway stock trades at the bottom of the page.

Jean Holloway biography

Jean F. Holloway, Esq. is Senior Vice President, Chief Compliance Officer, General Counsel, Secretary of the Company. She was appointed to the position of Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary in January 2016. She previously served as Vice President, General Counsel, and Secretary beginning in April 2015 and was subsequently appointed to the additional position of Chief Compliance Officer in October 2015. Prior to joining CryoLife, she held various positions, including Vice President, General Counsel and Secretary of Bard, Deputy General Counsel, Medtronic, Inc., Vice President, Litigation, Boston Scientific, Inc., and Deputy General Counsel, Guidant Corporation. Ms. Holloway also spent nearly 15 years in private practice as a trial lawyer at Dorsey & Whitney, Faegre & Benson and Sidley & Austin. She clerked for two years on the Seventh Circuit Court of Appeals for the Honorable Luther M. Swygert. Ms. Holloway has a J.D./M.B.A. from the University of Chicago and two undergraduate degrees from Yale University in engineering and political science.

What is the salary of Jean Holloway?

As the Senior Vice President、 Chief Compliance Officer、 General Counsel、 Secretary of Artivion Inc, the total compensation of Jean Holloway at Artivion Inc is 1,391,060$. There are 2 executives at Artivion Inc getting paid more, with James Mackin having the highest compensation of 6,453,540$.

How old is Jean Holloway?

Jean Holloway is 62, she's been the Senior Vice President、 Chief Compliance Officer、 General Counsel、 Secretary of Artivion Inc since 2016. There are 6 older and 17 younger executives at Artivion Inc. The oldest executive at Artivion Inc is Ronald McCall, 83, who is the Presiding Independent Director.

What's Jean Holloway's mailing address?

Jean's mailing address filed with the SEC is 1655 ROBERTS BLVD., NW, , KENNESAW, GA, 30144.

Insiders trading at Artivion Inc

Over the last 21 years, insiders at Artivion Inc have traded over 18,346,910$ worth of Artivion Inc stock and bought 91,700 units worth 1,086,548$ . The most active insiders traders include Steven G Anderson、Thomas F Ackerman、James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of 211,842$. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth 46,425$.

What does Artivion Inc do?

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.

Complete history of Ms. Holloway stock trades at Artivion Inc

Artivion Inc executives and stock owners

Artivion Inc executives and other stock owners filed with the SEC include:

• James Mackin,
  Chairman of the Board, President, Chief Executive Officer, Director
• D. Ashley Lee,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Jean Holloway,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Michael Simpson,
  Senior Vice President - Regulatory Affairs and Quality Assurance
• John Davis,
  Senior Vice President - Global Sales and Marketing
• James Patrick Mackin,
  Chairman, Pres & CEO
• Scott Capps,
  Vice President - Clinical Research
• David Ashley Lee CPA, CPA,
  Exec. VP, COO & CFO
• Jean F. Holloway Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• John E. Davis,
  Sr. VP of Global Sales & Marketing
• Harvey Morgan,
  Independent Director
• Daniel Bevevino,
  Independent Director
• Ronald McCall,
  Presiding Independent Director
• Thomas Ackerman,
  Independent Director
• Jon Salveson,
  Independent Director
• James Bullock,
  Independent Director
• Jeffrey Burbank,
  Independent Director
• Marna Borgstrom,
  Independent Director
• Greg Chodaczek,
  IR Contact Officer
• Matthew Getz,
  Vice President - Human Resources
• Dennis Maier,
  Vice President - Operations
• Amy Horton,
  Chief Accounting Officer, Vice President
• Thomas Bogenschutz,
  Senior Vice President - EMEA, General Manager - Hechingen
• Dr. Marshall S. Stanton,
  Sr. VP of Clinical Research & Chief Medical Officer
• Joshua Wells,
  Sr. Director of Bus. Devel.
• Matthew A. Getz,
  VP of HR
• Amy D. Horton CPA, CPA,
  VP & Chief Accounting Officer
• Sherry M Saurini,
  VP, Quality
• C Elkins Ronald,
  Director
• James Benson,
  Director
• James M Mc Dermid,
  SVP, CHRO
• David C Gale,
  VP-Research and Development
• William Robert Matthews,
  Senior VP, Operations, Quality
• Thomas J Bogenschuetz,
  VP, EMEA & General Manager
• Bruce G. Anderson,
  VP, US Sales and Marketing
• Jeffrey W Burris,
  Vice President & Gen. Counsel
• Gerald B Seery,
  Sr. VP, Sales and Marketing
• John M Cook,
  Director
• David P. Lang,
  Sr. VP, Intl Sales & Marketing
• Steven G Anderson,
  President, CEO and Chairman
• Thomas J Lynch,
  VP - Reg. Aff./Quality Assur.
• Capital Management Oss,
  10% owner
• Philip A Theodore,
  VP, General Counsel
• Michaelstark Brian Jay Roth,
  
• Sidney B Ashmore,
  Vice President of Marketing
• Virginia C Lacy,
  Director
• Dyne Bruce J Md Van,
  Director
• Albert E Heacox,
  Sr. VP-Laboratory Operations
• Vander James C Wyk,
  VP - Product Integrity
• Kirby S Black,
  Sr. Vice President, R&D
• David Fronk,
  VP - Clinical Research
• Rochelle L. Maney,
  VP, Quality
• Franz Peter Barthold,
  VP, Research & Development
• Marshall S. Stanton,
  SVP, Clinical & MD Affair
• Anthony B. Semedo,
  Director